

AMENDMENTS TO THE DRAWINGS


Please replace the drawings with the attached formal drawing sheets (forty-six (46) different sheets, Figs. 1A-9E) submitted herewith.



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
1/46

ACGTTGACAC AGGAATGAAG AGTGTATTGG CTGAATCTTC AAGCAGAGGC GATATTGACC 60
ATGTGCTTT TAAATTGCC TGGGTGACCC GCCCACTTGG TGTAAAAGAA GAACCGGCCA 120
AAGGGAGGGC CTGAAGGACC TCCACAGGAG TGTGAGCAGC ACTGCTTCAG CAACAAAGCC 180
TCAGGGTCCAC ATCTTGAA GAAT ATG GCC ACT TCC TGG GGG GCT GTC RTC 231
Met Ala Thr Ser Trp Gly Ala Val Phe
1 5
ATG CTG ATC ATA GCC TGC GTT GGC AGC ACT GTC TTC TAC AGA GAA CAG 279
Met Leu Ile Ala Cys Val Gly Ser Thr Val Phe Tyr Arg Glu Gln
10 15
CAG ACC TGG TTT GAA GGT GTC TTC TTG TCT ATG TGC CCC ATT AAT 327
Gln Thr Trp Phe Glu Gly Val Phe Leu Ser Ser Met Cys Pro Ile Asn
30 35
GTC AGT GCC GGC ACC TTT TAT GGA ATT ATG TTT GAT GCG GGC AGC ACT 375
Val Ser Ala Gly Thr Phe Tyr Gly Ile Met Phe Asp Ala Gly Ser Thr
45 50
GGA GCT CGG ATT CAT GTT TAC ACT TTT GTG CAG AAA ACA GCA GGA CAG 423
Gly Ala Arg Ile His Val Tyr Thr Phe Val Gln Lys Thr Ala Gly Gln
60 65
70


FIG. 1A



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
2/46

ctc	ccc	ttt	ctg	gaa	ggg	att	ttt	gat	tct	gtg	aag	ccg	gga	ctt	471	
Leu	Pro	Phe	Leu	Glu	Gly	Glu	Ile	Phe	Asp	Ser	Val	Lys	Pro	Gly	Leu	
75															85	
TCT	GCT	TTT	GTG	GAT	CAG	CCC	AAA	CAG	GGT	GCT	GAG	ACT	GTC	CAG	GAG	519
Ser	Ala	Phe	Val	Asp	Gln	Pro	Lys	Gln	Gly	Ala	Glu	Thr	Val	Gln	Glu	105
90															95	
CTC	TTG	GAG	GTG	GCC	AAA	GAC	TCG	ATC	CCC	AGA	AGC	CAC	TGG	GAA	AGG	567
Leu	Leu	Glu	Val	Ala	Lys	Asp	Ser	Ile	Pro	Arg	Ser	His	Trp	Glu	Arg	110
															115	
ACC	CCC	GTG	GTT	CTG	AAA	GCA	ACG	GCC	GGA	CTC	CGT	TTG	CTG	CCT	GAG	615
Thr	Pro	Val	Val	Leu	Lys	Ala	Thr	Ala	Gly	Leu	Arg	Leu	Leu	Pro	Glu	125
															130	
CAG	AAA	GCC	CAG	GCT	CTG	CTC	TTG	GAG	GTA	GAG	ATC	TTC	AAG	AAT	663	
Gln	Lys	Ala	Gln	Ala	Leu	Leu	Glu	Val	Glu	Glu	Ile	Phe	Lys	Asn	140	
															145	
TCA	CCT	TTC	CTG	GTC	CCA	GAT	GGC	AGC	GTT	AGC	ATC	ATG	GAT	GGG	TCC	711
Ser	Pro	Phe	Leu	Val	Pro	Asp	Gly	Ser	Val	Ser	Ile	Met	Asp	Gly	Ser	155
															160	
															165	

FIG. 1B



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
3/46

TAT	GAA	GGC	ATA	CTA	GCC	TGG	GTT	ACC	GTG	AAC	TTT	CTA	ACA	GGT	CAG	759
Tyr	Glu	Gly	Ile	Leu	Ala	Trp	Val	Thr	Val	Asn	Phe	Leu	Thr	Gly	Gln	170
																175
																180
																185
CTG	CAT	GGT	CGT	GGC	CAG	GAG	ACT	GTG	GGG	ACC	CTT	GAC	CTG	GGG	GGT	807
Leu	His	Gly	Gly	Arg	Gly	Gln	Glu	Thr	Val	Gly	Thr	Leu	Asp	Leu	Gly	190
																195
																200
GCC	TCC	ACC	CAA	ATC	ACG	TTT	CTA	CCC	CAG	TTT	GAG	AAA	ACC	CTG	GAA	855
Ala	Ser	Thr	Gln	Ile	Thr	Phe	Leu	Pro	Gln	Phe	Glu	Lys	Thr	Leu	Glu	195
																210
																215
CAA	ACA	CCT	AGG	GGC	TAC	CTC	ACT	TCC	TTT	GAG	ATG	TTT	AAC	AGC	ACT	903
Gln	Thr	Pro	Arg	Gly	Tyr	Leu	Thr	Ser	Phe	Glu	Met	Phe	Asn	Ser	Thr	220
																225
																230
TTT	AAG	CTC	TAT	ACA	CAT	AGT	TAC	TTG	GGA	TTT	GGA	CTG	AAA	GCT	GCA	951
Phe	Lys	Leu	Tyr	Thr	His	Ser	Tyr	Leu	Gly	Phe	Gly	Leu	Lys	Ala	Ala	235
																240
																245
AGA	CTG	GCA	ACT	CTG	GGA	GCC	CTG	GAA	GCA	AAA	GGG	ACT	GAT	GGA	CAT	999
Arg	Leu	Ala	Thr	Leu	Gly	Ala	Leu	Glu	Ala	Lys	Gly	Thr	Asp	Gly	His	250
																260
																265

FIG. 1C



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES

AND NUCLEIC ACIDS

Applicants: Chadwick et al.

Docket No. 28110/36120C

4/46

ACG	TTT	CGA	AGT	GCC	TGT	TTA	CCA	AGA	TGG	TTG	GAA	GCA	GAG	TGG	ATC	1047
Thr	Phe	Arg	Ser	Ala	Cys	Leu	Pro	Arg	Trp	Leu	Glu	Ala	Glu	Trp	Ile	
																270
																280
																285
																290
																295
																295
GGC	TTT	GAA	CCC	TGC	TAT	GCG	GAA	GTG	CTG	AGG	GTA	GTA	CAG	GGG	AAA	1095
Gly	Phe	Glu	Pro	Cys	Tyr	Ala	Glu	Val	Leu	Arg	Val	Val	Gln	Gly	Glu	Met
																300
																305
																310
																310
																315
																320
																320
																325
																325
TAC	TAC	TAC	GAT	CGA	GCC	GCT	GAC	ACA	CAC	TTG	ATC	GAT	TAT	GAA	AAG	1191
Tyr	Tyr	Tyr	Asp	Arg	Ala	Ala	Asp	Thr	His	Leu	Ile	Asp	Tyr	Ala	Phe	Ser
																315
																320
																320
																325
																325
																325
																325
GGC	GGG	GTT	TTA	AAA	GTT	GAA	GAT	TTT	GAA	AGA	AAA	GCC	AGA	GAA	GTG	1287
Gly	Gly	Val	Leu	Lys	Val	Glu	Asp	Phe	Glu	Arg	Lys	Ala	Arg	Glu	Val	360
																350
																355
																355
																355

FIG. 1D



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
5/46

TGT	GAC	AAC	TTG	GGG	AGC	TTC	TCC	TCG	GGC	AGT	CCT	TTC	CTC	TGC	ATG	1335
Cys	Asp	Asn	Leu	Gly	Ser	Phe	Ser	Ser	Gly	Ser	Pro	Phe	Leu	Cys	Met	365
																375
GAC	CTC	ACT	TAC	ATC	ACA	GCC	CTG	TTG	AAA	GAT	GGT	TTG	GGC	TTT	GCC	1383
Asp	Leu	Thr	Tyr	Ile	Thr	Ala	Leu	Leu	Lys	Asp	Gly	Leu	Gly	Phe	Ala	380
																390
GAA	CGG	CAC	CCT	CTT	ACA	GCT	CAC	AAA	GAA	AGT	GAA	CAA	CAT	AGA	GAC	1431
Glu	Arg	His	Pro	Leu	Thr	Ala	His	Lys	Glu	Ser	Glu	Gln	His	Arg	Asp	395
																405
TGG	TTG	GGC	CTT	GGG	GGC	CAC	CTT	TCA	CCT	GCT	CCA	GTC	TCT	GGG	CAT	1479
Trp	Leu	Gly	Leu	Gly	Gly	His	Leu	Ser	Pro	Ala	Pro	Val	Ser	Gly	His	410
																420
CAC	CAG	CTG	AGG	CCA	AGC	TCC	ACC	TCT	GAA	GCC	TGC	ATT	TCT	GAA	CCA	1527
His	Gln	Leu	Arg	Pro	Ser	Ser	Thr	Ser	Glu	Ala	Cys	Ile	Ser	Glu	Pro	430
																435
GTT	TTC	TCA	CAG	GAA	GGC	GTG	GAC	TCA	GAG	ACA	TTT	TCT	GAC	CTC	TCT	1575
Val	Phe	Ser	Gln	Glu	Gly	Val	Asp	Ser	Glu	Thr	Phe	Ser	Asp	Leu	Ser	445
																450
																455

FIG. 1E



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
6/46

GGA AAA GCC TGG CCC GAA ACC CGT TAACTGGTT TATAAGGAGG GAGGGTTT 1629
Gly Lys Ala Trp Pro Glu Thr Arg
460 465

TAGATGAGTC TTGCTCTTGA GCCTAGTGAT TTGGGCTTCA ATGATTGCA CATCTAATGT 1689
GAATAGCTCC TAACCACCTG GTGGGTGCAT GGCTGGCACC AGACTGTAAA TCTTTGGAA 1749
TTCCTTGTC AGAGTCTGC AAAGGAAAAA AGAGAAAAGG TTTGGAACTC CATGCTAGAT 1809
TGCAGATTCA GAGACAGGTC CCTGGGGACC AAAGAACAAAT CTCGTTCAA CCCTGGATG 1869
CCTCATGCT TTGAATGGAT TCATTGGTC TTATAAGCTG ATTACTGAA ATCCCATAAC 1929
CCATCAATGC TGTTAATTGTT TTCTTCTCTA CCCTTATTAC ATTCCCTACC CTAAAGCCT 1989
GGGGGAAATA CCTGGTTTG CTTCCCCATCT ATAATGAGA AAGAGGGGG AAAAGATACT 2049
GTATTAGAAT TTGTGTGATC CTGTGGCACA ATAGATCAAC CAACCCATT AAAGCTTAA 2109
AAAAAA

2119

FIG. 1F

Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS

Applicants: Chadwick et al.

Docket No. 28110/36120C

7/46

peaNTPase	1	- - - MELL <u>L</u> <u>I</u> <u>K</u> LITFLLFSMPAITSSQYLGN <u>N</u> <u>N</u> <u>L</u> <u>L</u> T <u>S</u> R <u>K</u> I <u>F</u> LK <u>Q</u> E <u>E</u> ISSYAVVFDAGSTGSR
potapyrase	1	<u>M</u> <u>L</u> <u>N</u> <u>Q</u> <u>N</u> SH <u>F</u> <u>I</u> F <u>I</u> <u>I</u> A <u>I</u> <u>F</u> L <u>V</u> <u>L</u> P <u>L</u> S <u>L</u> S <u>K</u> V <u>N</u> A <u>Q</u> <u>I</u> P <u>L</u> R <u>R</u> H <u>L</u> L <u>S</u> <u>E</u> <u>S</u> <u>E</u> - - HYA <u>V</u> I <u>F</u> D <u>A</u> G <u>S</u> T <u>G</u> S <u>R</u>
mNTPase	1	<u>M</u> <u>A</u> <u>T</u> <u>S</u> W <u>G</u> <u>A</u> <u>V</u> <u>F</u> <u>M</u> <u>L</u> <u>I</u> <u>I</u> A <u>C</u> <u>V</u> <u>G</u> <u>S</u> <u>T</u> <u>V</u> <u>F</u> <u>Y</u> <u>R</u> Q <u>Q</u> <u>T</u> W <u>F</u> <u>E</u> <u>G</u> <u>V</u> <u>F</u> <u>L</u> <u>S</u> <u>S</u> <u>M</u> <u>C</u> <u>P</u> <u>I</u> <u>N</u> <u>V</u> <u>S</u> <u>A</u> <u>G</u> <u>T</u> <u>F</u> <u>Y</u> <u>G</u> <u>I</u> <u>M</u> <u>F</u> D <u>A</u> G <u>S</u> T <u>G</u> T <u>R</u>
yGDPase	1	K <u>T</u> <u>P</u> <u>E</u> <u>D</u> <u>I</u> <u>S</u> <u>I</u> <u>L</u> P <u>V</u> <u>N</u> <u>D</u> <u>E</u> <u>P</u> <u>G</u> <u>Y</u> <u>L</u> <u>Q</u> <u>D</u> <u>S</u> <u>K</u> <u>T</u> <u>E</u> Q <u>N</u> <u>Y</u> <u>P</u> <u>E</u> <u>L</u> <u>A</u> <u>D</u> <u>A</u> <u>V</u> <u>K</u> <u>S</u> <u>Q</u> <u>T</u> <u>S</u> <u>O</u> <u>T</u> <u>C</u> <u>S</u> <u>E</u> <u>E</u> <u>H</u> <u>K</u> <u>Y</u> <u>V</u> <u>I</u> <u>M</u> <u>I</u> <u>D</u> <u>A</u> <u>G</u> <u>S</u> <u>T</u> <u>G</u> S <u>R</u>
peaNTPase	57	I <u>H</u> <u>V</u> <u>V</u> <u>H</u> <u>F</u> <u>N</u> <u>Q</u> <u>N</u> <u>L</u> <u>D</u> <u>L</u> <u>H</u> <u>H</u> <u>I</u> <u>G</u> <u>K</u> <u>G</u> <u>V</u> <u>E</u> <u>Y</u> <u>Y</u> <u>N</u> <u>K</u> <u>I</u> <u>T</u> <u>P</u> <u>G</u> <u>L</u> <u>S</u> <u>S</u> <u>Y</u> <u>A</u> <u>N</u> <u>N</u> <u>P</u> <u>E</u> <u>Q</u> <u>A</u> <u>K</u> <u>S</u> <u>L</u> <u>I</u> <u>P</u> <u>L</u> <u>E</u> <u>Q</u> <u>A</u> <u>E</u> <u>D</u> <u>V</u> <u>V</u> <u>P</u> <u>D</u> <u>D</u> <u>L</u> <u>Q</u> <u>P</u>
potapyrase	59	V <u>H</u> <u>V</u> <u>F</u> <u>R</u> <u>F</u> <u>D</u> <u>E</u> <u>K</u> <u>L</u> <u>G</u> <u>L</u> <u>P</u> <u>I</u> <u>G</u> <u>N</u> <u>N</u> <u>I</u> <u>E</u> <u>Y</u> <u>F</u> <u>M</u> <u>A</u> <u>T</u> <u>E</u> <u>P</u> <u>G</u> <u>L</u> <u>S</u> <u>S</u> <u>Y</u> <u>A</u> <u>E</u> <u>D</u> <u>P</u> <u>K</u> <u>A</u> <u>A</u> <u>N</u> <u>S</u> <u>L</u> <u>E</u> <u>P</u> <u>L</u> <u>D</u> <u>G</u> <u>A</u> <u>E</u> <u>G</u> <u>V</u> <u>V</u> <u>P</u> <u>Q</u> <u>E</u> <u>L</u> <u>Q</u> <u>S</u>
mNTPase	61	I <u>H</u> <u>V</u> <u>V</u> <u>T</u> <u>F</u> <u>V</u> <u>Q</u> <u>K</u> <u>T</u> <u>A</u> <u>G</u> <u>Q</u> <u>L</u> <u>P</u> <u>F</u> <u>L</u> <u>E</u> <u>G</u> <u>E</u> <u>I</u> <u>F</u> <u>D</u> <u>S</u> <u>V</u> <u>K</u> <u>P</u> <u>G</u> <u>L</u> <u>S</u> <u>A</u> <u>F</u> <u>V</u> <u>D</u> <u>Q</u> <u>P</u> <u>K</u> <u>Q</u> <u>G</u> <u>A</u> <u>E</u> <u>T</u> <u>V</u> <u>Q</u> <u>E</u> <u>L</u> <u>E</u> <u>V</u> <u>A</u> <u>K</u> <u>D</u> <u>S</u> <u>I</u> <u>P</u> <u>R</u> <u>S</u> <u>H</u> <u>W</u> <u>E</u>
yGDPase	61	V <u>H</u> <u>I</u> <u>Y</u> <u>K</u> <u>F</u> <u>D</u> <u>V</u> <u>C</u> <u>T</u> <u>S</u> <u>-</u> <u>-</u> <u>P</u> <u>P</u> <u>T</u> <u>L</u> <u>L</u> <u>D</u> <u>E</u> <u>K</u> <u>F</u> <u>D</u> <u>M</u> <u>L</u> <u>E</u> <u>P</u> <u>G</u> <u>L</u> <u>S</u> <u>S</u> <u>F</u> <u>D</u> <u>T</u> <u>D</u> <u>S</u> <u>V</u> <u>G</u> <u>A</u> <u>A</u> <u>N</u> <u>S</u> <u>L</u> <u>D</u> <u>P</u> <u>L</u> <u>K</u> <u>V</u> <u>A</u> <u>M</u> <u>N</u> <u>V</u> <u>P</u> <u>I</u> <u>K</u> <u>A</u> <u>R</u> <u>S</u> <u>=</u>
peaNTPase	117	K <u>T</u> <u>P</u> <u>V</u> <u>R</u> <u>L</u> <u>G</u> <u>A</u> <u>T</u> <u>A</u> <u>G</u> <u>L</u> <u>R</u> <u>L</u> <u>L</u> <u>N</u> <u>G</u> <u>D</u> <u>A</u> <u>S</u> <u>E</u> <u>K</u> <u>I</u> <u>L</u> <u>Q</u> <u>S</u> <u>V</u> <u>R</u> <u>D</u> <u>M</u> <u>L</u> <u>S</u> <u>N</u> <u>R</u> <u>S</u> <u>T</u> <u>F</u> <u>-</u> <u>N</u> <u>Q</u> <u>P</u> <u>D</u> <u>A</u> <u>V</u> <u>S</u> <u>I</u> <u>I</u> <u>D</u> <u>G</u> <u>T</u> <u>Q</u> <u>E</u> <u>G</u> <u>S</u> <u>Y</u> <u>L</u> <u>W</u> <u>V</u> <u>T</u>
potapyrase	119	E <u>T</u> <u>P</u> <u>L</u> <u>E</u> <u>G</u> <u>A</u> <u>T</u> <u>A</u> <u>G</u> <u>L</u> <u>R</u> <u>M</u> <u>L</u> <u>K</u> <u>G</u> <u>D</u> <u>A</u> <u>E</u> <u>K</u> <u>I</u> <u>L</u> <u>Q</u> <u>A</u> <u>V</u> <u>R</u> <u>N</u> <u>L</u> <u>V</u> <u>K</u> <u>N</u> <u>Q</u> <u>S</u> <u>T</u> <u>F</u> <u>-</u> <u>H</u> <u>S</u> <u>K</u> <u>D</u> <u>Q</u> <u>W</u> <u>V</u> <u>T</u> <u>I</u> <u>L</u> <u>D</u> <u>G</u> <u>T</u> <u>Q</u> <u>E</u> <u>G</u> <u>S</u> <u>Y</u> <u>M</u> <u>W</u> <u>A</u> <u>=</u>
mNTPase	121	R <u>T</u> <u>P</u> <u>V</u> <u>V</u> <u>L</u> <u>K</u> <u>A</u> <u>T</u> <u>A</u> <u>G</u> <u>L</u> <u>R</u> <u>L</u> <u>L</u> <u>P</u> <u>E</u> <u>Q</u> <u>K</u> <u>A</u> <u>Q</u> <u>A</u> <u>L</u> <u>L</u> <u>E</u> <u>V</u> <u>E</u> <u>I</u> <u>F</u> <u>K</u> <u>N</u> <u>-</u> <u>S</u> <u>P</u> <u>F</u> <u>-</u> <u>L</u> <u>V</u> <u>P</u> <u>D</u> <u>G</u> <u>S</u> <u>V</u> <u>S</u> <u>I</u> <u>M</u> <u>D</u> <u>G</u> <u>S</u> <u>Y</u> <u>E</u> <u>G</u> <u>I</u> <u>L</u> <u>A</u> <u>W</u> <u>V</u> <u>T</u>
yGDPase	119	C <u>T</u> <u>P</u> <u>V</u> <u>A</u> <u>V</u> <u>K</u> <u>A</u> <u>T</u> <u>A</u> <u>G</u> <u>L</u> <u>R</u> <u>L</u> <u>L</u> <u>G</u> <u>D</u> <u>A</u> <u>K</u> <u>S</u> <u>S</u> <u>K</u> <u>I</u> <u>L</u> <u>S</u> <u>A</u> <u>V</u> <u>R</u> <u>D</u> <u>H</u> <u>L</u> <u>E</u> <u>K</u> <u>D</u> <u>Y</u> <u>P</u> <u>F</u> <u>P</u> <u>V</u> <u>V</u> <u>E</u> <u>G</u> <u>D</u> <u>G</u> <u>V</u> <u>S</u> <u>I</u> <u>M</u> <u>G</u> <u>G</u> <u>D</u> <u>E</u> <u>F</u> <u>G</u> <u>V</u> <u>F</u> <u>A</u> <u>W</u> <u>I</u> <u>T</u>

FIG. 2A



**Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS**

Applicants: Chadwick et al.
Docket No. 28110/36120C
8/46



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
9/46

peaNTPase	328	<u>G Q K N L F A S S S F Y L P E D T G M V D A S T P N F I L R P V D I E T K A K E A C A L N F E D A K S T Y P F L D K K</u>
potapyrase	329	<u>G Q K N I H A S S F F Y D I G A Q V G I V D T K F P S A L A K P I Q Y L N A A K V A C Q T N V A D I K S I F P K T Q D R</u>
mNTPase	322	<u>G S A - F Y A F S Y Y D R A A D T H L I D Y E - K G G V L K V E D F E R K A R E V C D - N L G S F S S G S P - - -</u>
yGDPase	354	<u>E S N D I Y I F S Y Y D R T R P L G M P L S F T I L N E L N D L A R I V C K G E E T W N S V F S G I A G S - - L D E L</u>

peaNTPase	388	<u>N V A S Y V C M D L I Y Q Y V L V D G F G L D P L Q K I T S G K E I E Y Q D A I V E A W P L G N A V E A I S A L P K</u>
potapyrase	389	<u>N I - P Y L C M D L I Y E Y T L L V D G F G L N P H K E I T V I H D V Q Y K N Y L V G A A W P L G C A I D L V S S T T N</u>
mNTPase	374	<u>- - - F L C M D L T Y I T A L L K D G L G F A E R H P L T A H K E S E Q H R D W L G L G G H L S P A P V S G H H Q L R</u>
yGDPase	411	<u>E S D S H F C L D L S F Q V S L L H T G Y D I P L Q R E L R T G K K I A N K E - - - I G W C L G A S L P L L K A D N W</u>

peaNTPase	448	<u>F E R L M Y F V</u>
potapyrase	448	<u>K I R V A S S *</u>
mNTPase	430	<u>P S S T S E A C I S E P V F S Q E G V D S E T F S D L S G K A W P E T R *</u>
yGDPase	467	<u>K C K I Q S A</u>

FIG. 2C



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS

Applicants: Chadwick et al.
Docket No. 28110/36120C
10/46

ACRI

CD39	1	V K Y G I V I D A G S S H T S L Y I Y K W - - - - -	P A E K E N D T G V - - - - -	V H Q V E C R V K - - - - -	G P G I S - - - - -
ratCD39	1	V K Y G I V I D A G S S H T N L Y I Y K W - - - - -	P A E K E N D T G V - - - - -	V Q L L E E C Q V K - - - - -	G P G I S - - - - -
CD39L1	1	L K Y G I V I D A G S S H T S M F I Y K W - - - - -	P A D K E N D T G I - - - - -	V G Q H S S C D V P - - - - -	G G G I S - - - - -
chiATPase	1	F K Y G I V I D A G S S H T A V F I Y K W - - - - -	P A D K E N D T G V - - - - -	V S E H S M C D V E - - - - -	G P G I S - - - - -
peaNTPase	1	S S Y A V V F D A G S T T G S R I H V Y H F - - - - -	N Q - N L D L L H I G K G V E Y Y N - - - - -	K I T P G L S - - - - -	
potRROPI	1	E H Y A V I F D A G S T T G S R V H V F R F - - - - -	D E - K L G L L P I G N N I E Y F M - - - - -	A T E P G L S - - - - -	
YGDA1	1	H K Y V I M I D A G S T T G S R V H I Y K F - - - - -	D V C T S P - - P T L L D - E K F D - - - - -	M L E P G L S - - - - -	
mNTPase	1	T P Y G I M F D A G S T T G T R I H V Y T F - - - - -	V Q K T A G Q L P F L E G - E I F D - - - - -	S V K P G L S - - - - -	
hCD39L2	1	- - - - -	- - - - -	- - - - -	F K - - - - -
celegans	1	I K Y G V I C D A G S S G T R L F V Y T L K P L S G G L - - - - -	T N I D T - - - L - - -	I H E S E P V V K K V T P G L S - - - - -	
y71KD	1	D R F G I V I D A G S S G S R I H V F K W Q D T E S L L H A T N Q D S O S I L Q S V P H I H Q E K D W T F K L N P G L S - - - - -			

FIG. 3A




Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS

Applicants: Chadwick et al.
Docket No. 28110/36120C

		ACRII	
CD39	47	K <u>P</u> - V Q K V N E I G I - Y L L T D C M E R A R E V I P R - - S - Q H Q E T P V Y I L G A T A G M R L I R M E S E E F L A D	
ratCD39	47	K Y - A Q K T D E I <u>A A</u> - Y L A E C M K M S T E R I P A - - S K Q H Q - T P V Y I L G A T A G M R L I R M E S K Q S A D	
CD39L1	47	S Y - <u>A D N P S G A S Q</u> - S L V G C L E Q A L Q D V P K - - E R - H A G T P L Y I L G A T A G M R L I I N L T N P E A S T	
chiATPase	47	S Y - S S K P P A A G K - S L E H C L S Q A M R D V P K - - E K - H A D T P L Y I L G A T A G M R L I I D P P S Q T	11/46
peaNTPase	46	S Y - A N N P E Q A A K S - L I P L L E Q A E D V V P - - D D L Q P K T P V R I L G A T A G L R L I N - - G D A - S E	
potRROP1	46	S Y - A E D P K A A A N S - L E P L L D G A E G V V P - - Q E L Q S E T P L E L G A T A G L R M I K - - G D A - A E	
yGDA1	44	S P D T D S V - G A A N S - L D P L L K V A M N Y V P I - - K A R S C T P V A V K A T A G L R L I L - - G D A K S S	
mNTPase	46	A F - V D Q P K Q G A E T - V Q E L L E V A K D S I P R S H W E - - R - - T P V V I L K A T A G L R L I L - - P E Q K A Q	
hCD39L2	10	A Y - A D D V E K S A Q G - I R E L L D V A K Q D I P - - F D S G R P - T P L V I L K A T A G L R L I L - - P G E K A Q	
celegans	51	S F G - D K P E Q V V E - Y L T P L L R F A E E H I P Y E Q L G E - - T D L L I F A T A G M R L I L - - P E A Q K D	
y71KD	61	S P E - K K P Q D A Y K S H I K P L L D F A K N I I P E S H W S S - - C P V F I Q A T A G M R L I L - - P Q D I Q S	

FIG. 3B



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS


Applicants: Chadwick et al.
Docket No. 28110/36120C

12/46

ACR III

CD39	101	R <u>V</u> <u>L</u> <u>D</u> <u>V</u> <u>V</u> <u>E</u> <u>R</u> <u>S</u> <u>L</u> <u>S</u> <u>N</u> - <u>Y</u> <u>P</u> <u>F</u> - - - - <u>D</u> <u>F</u> <u>Q</u> <u>G</u> <u>A</u> <u>R</u> <u>I</u> <u>T</u> <u>G</u> <u>Q</u> <u>E</u> <u>G</u> <u>A</u> <u>Y</u> <u>G</u> <u>W</u> <u>I</u> <u>T</u> <u>N</u> <u>Y</u> <u>L</u> <u>G</u> <u>K</u> <u>F</u> <u>S</u> <u>Q</u> <u>K</u> <u>T</u> <u>R</u> <u>W</u> <u>F</u> <u>S</u> <u>I</u> <u>V</u> <u>P</u>
ratCD39	101	E <u>V</u> <u>L</u> <u>A</u> <u>A</u> <u>V</u> <u>S</u> <u>R</u> <u>S</u> <u>L</u> <u>K</u> <u>S</u> - <u>Y</u> <u>P</u> <u>F</u> - - - - <u>D</u> <u>F</u> <u>Q</u> <u>G</u> <u>A</u> <u>R</u> <u>I</u> <u>T</u> <u>G</u> <u>Q</u> <u>E</u> <u>G</u> <u>A</u> <u>Y</u> <u>G</u> <u>W</u> <u>I</u> <u>T</u> <u>N</u> <u>Y</u> <u>L</u> <u>G</u> <u>R</u> <u>F</u> <u>T</u> <u>Q</u> <u>E</u> <u>Q</u> <u>S</u> <u>W</u> <u>L</u> <u>N</u> <u>F</u> <u>I</u> <u>S</u>
CD39L1	101	S <u>V</u> <u>L</u> <u>M</u> <u>A</u> <u>V</u> <u>T</u> <u>T</u> <u>H</u> <u>T</u> <u>L</u> <u>Q</u> - <u>Y</u> <u>P</u> <u>F</u> - - - - <u>D</u> <u>F</u> <u>R</u> <u>G</u> <u>A</u> <u>R</u> <u>I</u> <u>L</u> <u>S</u> <u>Q</u> <u>Q</u> <u>E</u> <u>G</u> <u>V</u> <u>F</u> <u>G</u> <u>W</u> <u>V</u> <u>T</u> <u>A</u> <u>N</u> <u>Y</u> <u>L</u> <u>E</u> <u>N</u> <u>F</u> <u>I</u> - <u>K</u> <u>Y</u> <u>G</u> <u>W</u> <u>V</u> <u>G</u> - - R
chitATPase	101	- C <u>L</u> <u>S</u> <u>A</u> <u>V</u> <u>M</u> <u>A</u> <u>T</u> <u>L</u> <u>K</u> <u>S</u> - <u>Y</u> <u>P</u> <u>F</u> - - - - <u>D</u> <u>F</u> <u>G</u> <u>G</u> <u>A</u> <u>K</u> <u>I</u> <u>L</u> <u>S</u> <u>G</u> <u>E</u> <u>E</u> <u>G</u> <u>V</u> <u>F</u> <u>G</u> <u>W</u> <u>I</u> <u>T</u> <u>A</u> <u>N</u> <u>Y</u> <u>L</u> <u>E</u> <u>N</u> <u>F</u> <u>I</u> - <u>K</u> <u>R</u> <u>G</u> <u>W</u> <u>L</u> <u>G</u> - - E
peaNTPase	97	K <u>I</u> <u>L</u> <u>Q</u> <u>S</u> <u>V</u> <u>R</u> <u>D</u> <u>M</u> <u>L</u> <u>S</u> <u>N</u> <u>R</u> <u>S</u> <u>T</u> <u>F</u> <u>N</u> - <u>V</u> <u>Q</u> <u>P</u> <u>D</u> - A - <u>V</u> <u>S</u> <u>I</u> <u>I</u> <u>D</u> <u>G</u> <u>T</u> <u>Q</u> <u>E</u> <u>G</u> <u>S</u> <u>Y</u> <u>L</u> <u>W</u> <u>V</u> <u>T</u> <u>V</u> <u>N</u> <u>Y</u> <u>A</u> <u>L</u> <u>G</u> <u>N</u> - - - - - L - - G
potRRop1	97	K <u>I</u> <u>L</u> <u>Q</u> <u>O</u> <u>A</u> <u>V</u> <u>R</u> <u>N</u> <u>L</u> <u>V</u> <u>K</u> <u>N</u> <u>Q</u> <u>S</u> <u>T</u> <u>F</u> <u>H</u> - - S <u>K</u> <u>D</u> - Q <u>W</u> <u>V</u> <u>T</u> <u>I</u> <u>L</u> <u>D</u> <u>G</u> <u>T</u> <u>Q</u> <u>E</u> <u>G</u> <u>S</u> <u>Y</u> <u>M</u> <u>W</u> <u>A</u> <u>A</u> <u>I</u> <u>N</u> <u>Y</u> <u>L</u> <u>G</u> <u>N</u> - - - - L - - G
YGDA1	95	K <u>I</u> <u>L</u> <u>S</u> <u>A</u> <u>V</u> <u>R</u> <u>D</u> <u>H</u> <u>L</u> <u>E</u> <u>K</u> <u>D</u> <u>Y</u> <u>P</u> <u>P</u> <u>P</u> <u>V</u> <u>V</u> <u>E</u> <u>G</u> <u>D</u> - Q - V <u>S</u> <u>I</u> <u>M</u> <u>G</u> <u>G</u> <u>D</u> <u>E</u> <u>R</u> <u>G</u> <u>V</u> <u>F</u> <u>A</u> <u>W</u> <u>I</u> <u>T</u> <u>N</u> <u>Y</u> <u>L</u> <u>G</u> <u>N</u> - - - - I <u>G</u> <u>A</u> <u>N</u> <u>G</u>
mNTPase	97	A <u>L</u> <u>L</u> <u>E</u> <u>V</u> <u>E</u> <u>E</u> <u>I</u> <u>F</u> - <u>K</u> <u>N</u> <u>S</u> <u>P</u> <u>F</u> - <u>L</u> <u>V</u> - <u>P</u> <u>D</u> - G <u>S</u> <u>V</u> <u>S</u> <u>I</u> <u>M</u> <u>D</u> <u>G</u> <u>S</u> <u>Y</u> <u>E</u> <u>G</u> <u>I</u> <u>L</u> <u>A</u> <u>W</u> <u>V</u> <u>T</u> <u>V</u> <u>N</u> <u>F</u> <u>L</u> <u>T</u> <u>G</u> <u>Q</u> - - - - L <u>H</u> <u>G</u> <u>R</u> <u>G</u>
hCD39L2	61	K <u>L</u> <u>L</u> <u>Q</u> <u>K</u> <u>V</u> <u>K</u> <u>E</u> <u>Y</u> <u>L</u> - K <u>H</u> <u>S</u> <u>P</u> <u>F</u> - <u>L</u> <u>V</u> - <u>G</u> <u>D</u> - D <u>C</u> <u>V</u> <u>S</u> <u>I</u> <u>M</u> <u>N</u> <u>G</u> <u>T</u> <u>D</u> <u>E</u> <u>G</u> <u>V</u> <u>S</u> <u>A</u> <u>W</u> <u>X</u> <u>T</u> <u>I</u> <u>N</u> <u>F</u> <u>L</u> <u>T</u> <u>G</u> <u>S</u> - - - - L <u>K</u> <u>T</u> <u>P</u> <u>G</u>
c elegans	102	A <u>I</u> <u>I</u> <u>K</u> <u>N</u> <u>L</u> <u>Q</u> <u>N</u> <u>G</u> <u>L</u> <u>K</u> <u>S</u> <u>V</u> <u>T</u> <u>A</u> <u>R</u> <u>V</u> <u>S</u> <u>D</u> - - - S <u>N</u> <u>I</u> <u>R</u> <u>I</u> <u>D</u> <u>G</u> <u>A</u> <u>W</u> <u>E</u> <u>C</u> <u>I</u> <u>Y</u> <u>S</u> <u>W</u> <u>I</u> <u>V</u> <u>N</u> <u>I</u> <u>L</u> <u>G</u> <u>R</u> - - - F - D - -
y71KD	113	S <u>I</u> <u>I</u> <u>L</u> <u>D</u> <u>G</u> <u>L</u> <u>C</u> <u>Q</u> <u>G</u> <u>L</u> <u>K</u> <u>H</u> <u>P</u> <u>A</u> <u>R</u> <u>E</u> <u>P</u> <u>L</u> <u>E</u> <u>D</u> <u>C</u> <u>S</u> - A <u>Q</u> <u>I</u> <u>Q</u> <u>V</u> <u>I</u> <u>D</u> <u>G</u> <u>E</u> <u>T</u> <u>E</u> <u>G</u> <u>L</u> <u>Y</u> <u>G</u> <u>H</u> - - - - F <u>N</u> <u>D</u> <u>Y</u> <u>N</u>

FIG. 3C



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES

AND NUCLEIC ACIDS

Applicants: Chadwick et al.

Docket No. 28110/36120C

13/46

		ACR IV
CD39	155	Y E T N N Q E T F G A L D L G G A S T Q V T F V P Q N Q
ratCD39	155	- D S Q K Q A T P G A L D L G G S S T Q V T F V P L N Q
CD39L1	152	W P R P R K G T L G A M D L G G A S T Q I T F E T T S P
chiATPase	151	W I Q S K K K T L G A M D F G G A S T Q I T F E T S D A I
peaNTPase	144	K K Y T K - - T V G V I D L G G G S V Q M A Y A V S K K
potRRP01	144	K D Y K S - - T T A T I D L G G G S V Q M A Y A I S N E
YGDA1	146	P K L - P - - T A A V P D L G G G S T Q I V F E P T F P I
mNTPase	146	Q E - - - T V G T L D L G G A S T Q I T F L P Q F E
hCD39L2	110	G S - - - S V G M L D L G G G S T Q I A F L P R V E
celegans	149	K E - N D S - K V G M I D M G G A S V Q I A F E I A - N E
y71KD	165	P E V S D H F T F G P M D M G G A S T Q I A F - - A P H D S

FIG. 3D



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
14/46

GTGGGGTCTGT ATCCCCGGGG TGGAGGCCGG GGTGGGCCGG GCCGGGCCGG GGGAGCCCCA 60
AAGACCGGGCT GCGGCCTGCT CCCCGGAAAAA GGGCACTCGT CTCCGGGGGT GTGGGGGAGC 120
GGCGGGTGCA TGGAAATGGGC TATGTGAATG AAAAAAGGTA TCCGTTATGA AACTTCCAGA 180
AAAACGAGCT ACATTTCAC GCAGCCGCAG CACGGTCCTT GGCAACAAG G ATG AGA 237
Met Arg
1
AAA ATA TCC AAC CAC CGG AGC CTG CGG GTG GCG AAG GTG GCA TAC CCC 285
Lys Ile Ser Asn His Gly Ser Leu Arg Val Ala Lys Val Ala Tyr Pro
5
CTG GGG CTG TGT GTG GGC GTG TTC ATC TAT GTT GCC TAC ATC AAG TGG 333
Leu Gly Leu Cys Val Gly Val Phe Ile Tyr Val Ala Tyr Ile Lys Trp
20
CAC CGG GCC ACC ACC CAG GCC TTC AGC ATC ACC AGG GCA GCC 381
His Arg Ala Thr Ala Thr Gln Ala Phe Phe Ser Ile Thr Arg Ala Ala
35
40
45
50

FIG. 4A



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
15/46

CCG	GGG	GCC	CGG	TGG	GGT	CAG	CAC	GCC	CCC	CTG	GGG	ACA	GCT	429		
Pro	Gly	Ala	Arg	Trp	Gly	Gln	Ala	His	Ser	Pro	Leu	Gly	Thr	Ala		
														65		
														60		
														55		
GCA	GAC	GGG	CAC	GAG	GTC	TTC	TAC	GGG	ATC	ATG	TTT	GAT	GCA	GGA	AGC	477
Ala	Asp	Gly	His	Glu	Vai	Phe	Tyr	Gly	Ile	Met	Phe	Asp	Ala	Gly	Ser	
																80
																75
ACT	GGC	ACC	CGA	GTA	CAC	GTC	TTC	CAG	TTC	ACC	CGG	CCC	CCC	AGA	GAA	525
Thr	Gly	Thr	Arg	Val	His	Val	Phe	Gln	Phe	Thr	Arg	Pro	Pro	Arg	Glu	
																95
																85
ACT	CCC	ACG	TTA	ACC	CAC	GAA	ACC	TTC	AAA	GCA	GTG	AAG	CCA	GGT	CTT	573
Thr	Pro	Thr	Leu	Thr	His	Glu	Thr	Phe	Lys	Ala	Val	Lys	Pro	Gly	Leu	
																110
																100
TCT	GCC	TAT	GCT	GAT	GTT	GAA	AAG	AGC	GCT	CAG	GGA	ATC	CGG	GAA	621	
Ser	Ala	Tyr	Ala	Asp	Asp	Val	Glu	Lys	Ser	Ala	Gln	Gly	Ile	Arg	Glu	
																125
																115
																130

FIG. 4B



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES

AND NUCLEIC ACIDS

Applicants: Chadwick et al.

Docket No. 28110/36120C

16/46

CTA	CTG	GAT	GTT	GCT	AAA	CAG	GAC	ATT	CCG	TTC	GAC	TTC	TGG	AAG	GCC	669
Leu	Leu	Asp	Val	Ala	Lys	Gln	Asp	Ile	Pro	Phe	Asp	Phe	Trp	Lys	Ala	
									140					145		
ACC	CCT	CTG	GTC	CTC	AAG	GCC	ACA	GCT	GGC	TTA	CGC	CTG	TTA	CCT	GGA	717
Thr	Pro	Leu	Val	Leu	Lys	Ala	Thr	Ala	Gly	Leu	Arg	Leu	Leu	Pro	Gly	
									155					160		
GAA	AAG	GCC	CAG	AAG	TTA	CTG	CAG	AAG	GTG	AAA	GAA	GTA	TTT	AAA	GCA	765
Glu	Lys	Ala	Gln	Lys	Leu	Leu	Gln	Lys	Val	Lys	Glu	Val	Phe	Lys	Ala	
									170					175		
TCG	CCT	TTC	CTT	GTA	GGG	GAT	GAC	TGT	GTT	TCC	ATC	ATG	AAC	GGA	ACA	813
Ser	Pro	Phe	Leu	Val	Gly	Asp	Asp	Cys	Val	Ser	Ile	Met	Asn	Gly	Thr	
									185					190		
GAT	GAA	GGC	GTT	TCG	GCG	TGG	ATC	ACC	ATC	AAC	TTC	CTG	ACA	GGC	AGC	861
Asp	Glu	Gly	Val	Ser	Ala	Trp	Ile	Thr	Ile	Asn	Phe	Leu	Thr	Gly	Ser	
									200					205		210
TTG	AAA	ACT	CCA	GGA	GGG	AGC	GTG	GGC	ATG	CTG	GAC	TTG	GGC	GGA	909	
Leu	Lys	Thr	Pro	Gly	Gly	Ser	Ser	Val	Gly	Met	Leu	Asp	Leu	Gly	Gly	
									215					220		225

FIG. 4C

**Title: METHODS AND COMPOSITIONS
 RELATING TO CD-39-LIKE POLYPEPTIDES
 AND NUCLEIC ACIDS**
Applicants: Chadwick et al.
Docket No. 28110/36120C
 17/46



GGA	TCC	ACT	CAG	ATC	GCC	TTC	CTG	CCA	CGC	GTG	GAG	GGC	ACC	CTG	CAG	957
Gly	Ser	Thr	Gln	Ile	Ala	Phe	Leu	Pro	Arg	Val	Glu	Gly	Thr	Leu	Gln	
																230
																240
GCC	TCC	CCA	CCC	GGC	TAC	CTG	ACG	GCA	CTG	CGG	ATG	TTT	AAC	AGG	ACC	1005
Ala	Ser	Pro	Pro	Gly	Tyr	Leu	Thr	Ala	Leu	Arg	Met	Phe	Asn	Arg	Thr	
																245
TAC	AAG	CTC	TAT	TCC	TAC	AGC	TAC	CTC	GGG	CTC	GGG	CTG	ATG	TCG	GCA	1053
Tyr	Lys	Leu	Tyr	Ser	Tyr	Ser	Tyr	Leu	Gly	Leu	Gly	Leu	Met	Ser	Ala	
																255
																260
CGC	CTG	GCG	ATC	CTG	GGC	GGC	GTG	GAG	GGG	CAG	CCT	GCT	AAG	GAT	GGA	1101
Arg	Leu	Ala	Ile	Leu	Gly	Gly	Val	Glu	Gly	Gly	Pro	Ala	Lys	Asp	Gly	
																275
																280
AAG	GAG	TTG	GTC	AGC	CCT	TGC	TTG	TCT	CCC	AGT	TTC	AAA	GGA	GAG	TGG	1149
Lys	Glu	Leu	Val	Ser	Pro	Cys	Leu	Ser	Pro	Ser	Phe	Lys	Gly	Glu	Trp	
																295
																305
GAA	CAC	GCA	GAA	GTC	ACG	TAC	AGG	GTT	TCA	GGG	CAG	AAA	GCA	GCG	GCA	1197
Glu	His	Ala	Glu	Val	Thr	Tyr	Arg	Val	Ser	Gly	Gln	Lys	Ala	Ala	Ala	
																310
																320

FIG. 4D



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
18/46

AGC	CTG	CAC	GAG	CTG	TGT	GCT	GCC	AGA	GTG	TCA	GAG	GTC	CTT	CAA	AAC	1245
Ser	Leu	His	Glu	Leu	Cys	Ala	Ala	Arg	Val	Ser	Glu	Val	Leu	Gln	Asn	
																325
AGA	GTG	CAC	AGG	ACG	GAG	GAA	GTG	AAG	CAT	GTG	GAC	TTC	TAT	GCT	TTC	1293
Arg	Val	His	Arg	Thr	Glu	Glu	Val	Lys	His	Val	Asp	Phe	Tyr	Ala	Phe	
																340
TCC	TAC	TAT	TAC	GAC	CTT	GCA	GCT	GGT	GTG	GGC	CTC	ATA	GAT	GCG	GAG	1341
Ser	Tyr	Tyr	Tyr	Asp	Leu	Ala	Ala	Gly	Vai	Gly	Leu	Ile	Asp	Ala	Glu	
																350
AAG	GGA	GGC	AGC	CTG	GTG	GGG	GAC	TTC	GAG	ATC	GCA	GCC	AAG	TAC	1389	
Lys	Gly	Gly	Ser	Leu	Val	Gly	Asp	Phe	Glu	Ile	Ala	Ala	Lys	Tyr		
																375
GTG	TGT	CGG	ACC	CTG	GAG	ACA	CAG	CCG	CAG	AGC	CCC	TTC	TCA	TGC	1437	
Val	Cys	Arg	Thr	Ileu	Glu	Thr	Gln	Pro	Gln	Ser	Ser	Pro	Phe	Ser	Cys	
																390
ATG	GAC	CTC	ACC	TAC	GTC	AGC	CTG	CTA	CTC	CAG	GAG	TTC	GGC	TTT	CCC	1485
Met	Asp	Leu	Thr	Tyr	Tyr	Val	Ser	Leu	Leu	Leu	Gln	Glu	Phe	Gly	Phe	
																405
																410

FIG. 4E



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
19/46

AGG AGC AAA GTG CTG AAG CTC ACT CGG AAA ATT GAC AAT GTT GAG ACC
Arg Ser Lys Val Leu Lys Leu Thr Arg Lys Ile Asp Asn Val Glu Thr
420 425 430

AGC TGG GCT CTG GGG GCC ATT TTT CAT TAC ATC GAC TCC CTG AAC AGA
Ser Trp Ala Leu Gly Ala Ile Phe His Tyr Ile Asp Ser Leu Asn Arg
435 440 445 450

CAG AAG AGT CCA GCC TCA TAGTGGCGA GCCATCCCTG TCCCCGTCA
Gln Lys Ser Pro Ala Ser
455

CAGTGTCTGT GTGTCTGCAT AAACCCTCCT GTCCCTGGACG TGACTTCATC CTGAGGAGGCC 1629

ACAGCACAGG CCGTGCTGGC ACTTTCTGCA CACTGGCTCT GGGACTTGCA GAAGGCCTGG 1749

TGCTGCCCTG GCATCAGCCT CTTCCAGTCA CATCTGGCCA GAGGGCTGTC TGGACCTGGG 1809

CCCTGCTCAA TGCCACCTGT CTGCCCTGGC TCCAAGTGGG CAGGACCAGG ACAGAACAC 1869

AGGCACACAC TGAGGGCA GTGTGGCTCC CTGCCCTGTCC CATCCCCATG CCCCGTCCGC 1929

FIG. 4F



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
20/46

GGGGCTGTGG CTGCTGCTGT GCATGCCCT GCGATGGAG TCTTGTCTCC CAGCCTGTCA 1989
GTTTCCTCCC CAGGGCAGAG CTCCCCCTCC TGCAAGAGTC TGGGAGCCG TGAGGCTGT 2049
CCTGGCTGCT CTGGGAAGC CGAGGGACAG CCATAACACC CCCGGACAG TAGGTCTGGG 2109
CGGCACCACT GGGAACTCTG GACTTGAGTG TGTTTGCTCT TCCTTGGTA TGAATGTGTG 2169
AGTTCACCCA GAGGCCCTGCT CTCCCTCACAC ATTGTGTGGT TTGGGGTAA TGATGGAGGG 2229
AGACACCTCT TCATAGACGG CAGGTGCCCA CCTTCAGGG AGTCTCCCAG CATGGGGGA 2289
TGCGGGCAT GAGCTGCTGT AAACATTGG TGCTGTGCT GCTTGAGTGA CGTCTCTGTC 2349
GTGTGGTGC CAAGTGCTTG TGTAGAAACT GTGTTCTGAG CCCCCCTTTC TGGACACCAA 2409
CTGTGTCCCTG TGAATGGTATC GCTACTGTGA GCTGTCCCCG CCTAGCCAGG GCCATGTCTT 2469
AGGTGGAGCT GTGCCACGGG TCAGGTGAGC CACAGTCCCCA GAACCAAAGCT CTCGGGTGTCT 2529

FIG. 4G



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
21/46

CGGCCACCA TCGCCCCACC TCGGGCTGAC CCCACCTCCT CCATGGACAG TGTGAGCCCC 2589
GGCCGTGCA TCCTGCTCAG TGTGGGTCA GTGTCGGGC TGAGCCCTT GAGCTGCTTC 2649
AGTGAATGTA CAGTGCCGG CACGAGCTGA ACCTCATGTG TTCCACTCCC AATAAAAGGT 2709
TGACAGGGC TTCTCCTTCA AAAAAAAA AAAAAAAA AAAA 2762

FIG. 4H



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
22/46

FIG. 5A




FIG. 5B






FIG. 5C






Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
23/46

CD39L3



CD39L4





Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
24/46

ACCCACGGGT CTGGCCGGG GCCGCCCTG CGGCAGCGCT AGTCGCCTTC TCCGAATCGG 60

CTCCGCACAG CTTAGGAGAAA AG ATG TTC ACT GTG CTG ACC CGC CAA CCA TGT 112
Met Phe Thr Val Leu Thr Arg Gln Pro Cys
1 5 10

GAG CAA GCA GGC CTC AAG GCC CTC TAC CGA ACT CCA ACC ATC ATT GCC 160
Glu Gln Ala Gly Leu Lys Ala Leu Tyr Arg Thr Pro Thr Ile Ile Ala
15 20 25

TTC GTG GTC TTG CTT GTG AGT ATT GTG GTA CTT GTG AGT ATC ACT GTC 208
Leu Val Val Leu Leu Val Ser Ile Val Val Leu Val Ser Ile Thr Val
30 35 40

ATC CAG ATC CAC AAG CAA GAG GTC CTC CCTT CCA GGA CTG AAG TAT GGT 256
Ile Gln Ile His Lys Gln Glu Val Leu Pro Pro Gly Leu Lys Tyr Gly
45 50 55

ATT GTG CTG GAT GCC GGG TCT TCA AGA ACC ACA GTC TAC GTG TAT CAA 304
Ile Val Leu Asp Ala Gly Ser Ser Arg Thr Thr Val Tyr Val Tyr Gln
60 65 70

FIG. 6A



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES

AND NUCLEIC ACIDS

Applicants: Chadwick et al.

Docket No. 28110/36120C

25/46

TGG	CCA	GCA	GAA	AAA	GAG	AAT	AAT	ACC	GGA	GTG	GTC	AGT	CAA	ACC	TTC	352
Trp	Pro	Ala	Glu	Lys	Glu	Asn	Asn	Thr	Gly	Val	Val	Ser	Gln	Thr	Phe	
75					80					85				90		
AAA	TGT	AGT	GTG	AAA	GGC	TCT	GGA	ATC	TCC	AGC	TAT	GGA	AAT	AAC	CCC	400
Lys	Cys	Ser	Val	Lys	Gly	Ser	Gly	Ile	Ser	Ser	Tyr	Gly	Asn	Asn	Pro	
					95				100					105		
caa	gat	gtc	ccc	aga	gcc	ttt	gag	gag	tgt	atg	caa	aaa	gtc	aag	ggg	448
Gln	Asp	Val	Pro	Arg	Ala	Phe	Glu	Glu	Cys	Met	Gln	Lys	Val	Lys	Gly	
					110				115				120			
CAG	GTT	CCA	TCC	CAC	CTC	CAC	GGA	TCC	ACC	CCC	ATT	CAC	CTG	GGA	GCC	496
Gln	Val	Pro	Ser	His	Leu	His	Gly	Ser	Thr	Pro	Ile	His	Leu	Gly	Ala	
					125				130			135				
ACG	GCT	GGG	ATG	CGC	TTG	CTG	AGG	TTG	CAA	AAT	GAA	ACA	GCA	GCT	AAT	544
Thr	Ala	Gly	Met	Arg	Leu	Leu	Arg	Leu	Gln	Asn	Glu	Thr	Ala	Ala	Asn	
					140				145			150				
GAA	GTC	CTT	GAA	AGC	ATC	CAA	AGC	TAC	TTC	AAG	TCC	CAG	CCC	TTT	GAC	592
Glu	Val	Leu	Glu	Ser	Ile	Gln	Ser	Tyr	Phe	Lys	Ser	Gln	Pro	Phe	Asp	
					155				160			165			170	

FIG. 6B



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES

AND NUCLEIC ACIDS

Applicants: Chadwick et al.

Docket No. 28110/36120C

26/46

Phe	Arg	Gly	Ala	Gln	Ile	Ile	Ser	Gly	Gln	Glu	Gly	Val	Tyr	Gly	640	
															175	
															180	
															185	
TGG	ATT	ACA	GCC	AAC	TAT	TTA	ATG	GGA	AAT	TTC	CTG	GAG	AAG	AAC	CTG	688
Trp	Ile	Thr	Ala	Asn	Tyr	Leu	Met	Gly	Asn	Phe	Leu	Glu	Lys	Asn	Leu	
															190	
															195	
															200	
TGG	CAC	ATG	TGG	GTG	CAC	CCG	CAT	GGA	GTG	GAA	ACC	ACG	GGT	GCC	CTG	736
Trp	His	Met	Trp	Val	His	Pro	His	Gly	Val	Glu	Thr	Thr	Gly	Ala	Leu	
															205	
															210	
															215	
GAC	TTA	GGT	GGT	GCC	TCC	ACC	CAA	ATA	TCC	TTC	GTG	GCA	GGA	GAG	AAG	784
Asp	Leu	Gly	Gly	Ala	Ser	Thr	Gln	Ile	Ser	Phe	Val	Ala	Gly	Glu	Lys	
															220	
															225	
															230	
ATG	GAT	CTG	AAC	ACC	AGC	ATC	ATG	CAG	GTG	TCC	CTG	TAT	GGC	TAC	832	
Met	Asp	Leu	Asn	Thr	Ser	Asp	Ile	Met	Gln	Val	Ser	Leu	Tyr	Gly	Tyr	
															235	
															240	
															245	
GTA	TAC	ACG	CTC	TAC	ACA	CAC	AGC	TTC	CAG	TGC	TAT	GGC	CGG	AAT	GAG	880
Val	Tyr	Thr	Thr	His	Ser	Phe	Gln	Cys	Tyr	Gly	Arg	Asn	Glu			
															255	
															260	
															265	

FIG. 6C



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES

AND NUCLEIC ACIDS

Applicants: Chadwick et al.

Docket No. 28110/36120C

27/46

GCT GAG AAG TTT CTG GCA ATG CTC CCT CAG AAT TCT CCT ACC AAA
Ala Glu Lys Lys Phe Leu Ala Met Leu Gln Asn Ser Pro Thr Lys
270 275 280

AAC CAT CTC ACC AAT CCC TGT TAC CCT CGG GAT TAT AGC ATC AGC TTC
Asn His Leu Thr Asn Pro Cys Tyr Pro Arg Asp Tyr Ser Ile Ser Phe
285 290 295

ACC ATG GGC CAT GTA TTT GAT AGC CTG TGC ACT GTG GAC CAG AGG CCA
Thr Met Gly His Val Phe Asp Ser Leu Cys Thr Val Asp Gln Arg Pro
300 305 310

GAA AGT TAT AAC CCC AAT GAT GTC ATC ACT TTT GAA GGA ACT GGG GAC
Glu Ser Tyr Asn Pro Asn Asp Val Ile Thr Phe Glu Gly Thr Gly Asp
315 320 325

CCA TCT CTG TGT AAG GAG AAG GTG GCT TCC ATA TTT GAC TTC AAA GCT
Pro Ser Leu Cys Lys Glu Lys Val Ala Ser Ile Phe Asp Phe Lys Ala
335 340 345

TGC CAT GAT CAA GAA ACC TGT TCT TTT GAT GGG GTT TAT CAG CCA AAG
Cys His Asp Gln Glu Thr Cys Ser Phe Asp Gly Val Tyr Gln Pro Lys
350 355 360

FIG. 6D



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
28/46

ATT AAA GGG CCA TTT GTG GCT TTT GCA GGA TTC TAC TAC ACA GCC AGT	1216
Ile Lys Gly Pro Phe Val Ala Phe Ala Gly Phe Tyr Tyr Thr Ala Ser	
365	375
GCT TTA AAT CTT TCA GGT AGC TTT TCC CTG GAC ACC TTC AAC TCC AGC	1264
Ala Leu Asn Leu Ser Gly Ser Phe Ser Leu Asp Thr Phe Asn Ser Ser	
380	390
ACC TGG AAT TTC TGC TCA CAG AAT TGG AGT CAG CTC CCA CTG CTG CTC	1312
Thr Trp Asn Phe Cys Ser Gln Asn Trp Ser Gln Leu Pro Leu Leu Leu	
395	405
CCC AAA TTT GAT GAG GTA TAT GCC CGC TCT TAC TGC TTC TCA GCC AAC	1360
Pro Lys Phe Asp Glu Val Tyr Ala Arg Ser Tyr Cys Phe Ser Ala Asn	
415	420
TAC ATC TAC CAC TTG TTT GTG AAC GGT TAC AAA TTC ACA GAG GAG ACT	1408
Tyr Ile Tyr His Leu Phe Val Asn Gly Tyr Lys Phe Thr Glu Glu Thr	
430	435
TGG CCC CAA ATA CAC TTT GAA AAA GAA GTG GGG AAT AGC AGC ATA GCC	1456
Trp Pro Gln Ile His Phe Glu Lys Glu Val Gly Asn Ser Ser Ile Ala	
445	455

FIG. 6E



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
29/46

TGG TCT CTT GGC TAC ATG CTC AGC CTG ACC AAC CAG ATC CCA GCT GAA 1504
Trp Ser Leu Gly Tyr Met Leu Ser Thr Asn Gln Ile Pro Ala Glu
460 465 470

AGC CCT CTG ATC CGT CTG CCC ATA GAA CCA CCT GTC TTT GTG GGC ACC 1552
Ser Pro Leu Ile Arg Leu Pro Ile Glu Pro Val Phe Val Gly Thr
475 480 485 490

CTC GCT TTC ACA GTG GCA GCC TTG CTG TGT CTG GCA TTT CTT GCA 1600
Leu Ala Phe Thr Val Ala Ala Leu Leu Cys Leu Ala Phe Leu Ala
495 500 505

TAC CTG TGT TCA GCA ACC AGA AAG AGG CAC TCC GAG CAT GCC TTT 1648
Tyr Leu Cys Ser Ala Thr Arg Arg Lys Arg His Ser Glu His Ala Phe
510 515 520

GAC CAT GCA GTG GAT TCT GAC TGAGCCTCA AAGCAGCTCC TGGAGTCCAA 1699
Asp His Ala Val Asp Ser Asp
525

TGGCTGCTTA GAGTCAGGCCCT GGGTGGCACC AGGCCATGCA GGTGAAGTGG CTGCCTTCAG 1759

FIG. 6F



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
30/46

GAAATACAAC TAACTAAAAT CAAACACCTTA GGTACACGTGC CTCTCAAATA CTGATTCTG 1819
CCACAGCACC TCTTGAGGCA TCCCTTGGCT ATTCTGTGCA TATTGTTCTT CAGAGACCTC 1879
ACTACCCACA TGCTGTATCTA TTGGGAACAA GAGAAGAGAC AGGCCACTAA GGTCAAGGCTC 1939
TTTATATTTAA GTTCCCCAGA GGAAGAGTAA GTTGAGAAAGG TATCAGTTA ATGTTGAAGA 1999
ATTGACCTCA GGGCTCAGTT TCCATTCCC TCCCTCAGTA TTCTTCCTGG CAAGATAACCC 2059
ATTAAGCATT TCGCCAATCA GAATCTCATT TTATAGTTT TCCCATTGGT CTTTAACTAA 2119
GACTTTCTTG TAGCAATCTC GTAAGCAGTG AACCCCTCA GATCAGTAGA ATATAGTATC 2179
TGGGGAGAA GACTTACTTC CTTCAAGGGCA GCAGGCCACAG CCAGGCTTCT GTCAATACAGG 2239
TAGATCCCGA AGCACAGAGA CATAAAAAG GTCTCCCAGA AAACTATAGA CCATTCTCCA 2299
AGTGGAAATTTC CCACCTAGGG CTCTGGTCAC TAGATTGCAA CCTGTGTGTT TGTCAATCATC 2359
CTCATCTCAC CATTGTATG CTATGCCCTC CCATAAAAAC ACATTGATCC CTAGCAAGAT 2419

FIG. 6G



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
31/46

TATTGCATT CAGATTTAC TGCCTTGCT AGGCTTTGCT TAGCAAAGG GCTGACTTTC 2479
CATTGTATC ATGGTGTATA TATTTTGTC ACCATTCCCA CAAGTATACT TGATGTTGTC 2539
ATAGAACGAA CATCCTACTC TATGATTAC TAACCAATTAA CTTCCAGA TCATAGACCT 2599
CTCTGCATAG TAGTCATAGG TCTTGACTTT GGGGAAAGAA AAGGAAGCTG CAGGAATATT 2659
TATCTCAA GTCGAATGAG AAAGAACTCC AGCAAAATCCA ATGGCTACAA ACTAAAAAATC 2719
AGCATTATT CATATTGCTG TTTCTTAGCT GAATATGGAA TAAAGAACTA TTATTTATT 2779
TTGAAAAAA AAAAAGAA 2797

FIG. 6H

MAR 22 2004
PATENT & TRADEMARK OFFICE 1105

Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES

AND NUCLEIC ACIDS

Applicants: Chadwick et al.

Docket No. 28110/36120C

32/46

GGCGCCGGT TTTCCCTGTT CCTGGTCAAC AAAGAAATGT GGAGTGTCTT GGCTGAATCC 60

TCATACAGAC AAGATCATTA TGGTGCTGTT AGGTAGGACT TGTATCCAGA TGTAAAGGTTG 120

AAAAAGTGAT ATAATAAAGG AACCAAGGAG AAAATTAGA AGGAAAGAAA AAATTGCCTC 180

TGCAGGTGTG CGAGCAGGAT TGCTTCTGCA ACAAAAGCCT CCACCCAGCC ACATCTGGG 240


AAAAGA ATG GCC ACT TCT TGG GGC ACA GTC TTT TTC ATG CTG GTG GTA 288
Met Ala Thr Ser Trp Gly Thr Val Phe Phe Met Leu Val Val
1 5

TCC TGT GTT TGC AGC GCT GTC TCC CAC AGG AAC CAG CAG ACT TGG TTT 336
Ser Cys Val Cys Ser Ala Val Ser His Arg Asn Gln Gln Thr Trp Phe
15 20 25 30

GAG GGT ATC TTC CTG TCT TCC ATG TGC CCC ATC AAT GTC AGC GCC AGC 384
Glu Gly Ile Phe Leu Ser Ser Met Cys Pro Ile Asn Val Ser Ala Ser
35 40 45

ACC TTG TAT GGA ATT ATG TTT GAT GCA GGG AGC ACT GGA ACT CGA ATT 432
Thr Leu Tyr Gly Ile Met Phe Asp Ala Gly Ser Thr Gly Thr Arg Ile
50 55 60

FIG. 7A



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
33/46

CAT	GTT	TAC	ACC	TTT	GTG	CAG	AAA	ATG	CCA	GGA	CAG	CTT	CCA	ATT	CTA	480
His	Val	Tyr	Thr	Phe	Val	Gln	Lys	Met	Pro	Gly	Gln	Leu	Pro	Ile	Leu	65
																70
																75
GAA	GGG	GAA	GTT	TTT	GAT	TCT	GTG	AAG	CCA	GGA	CTT	TCT	GCT	TTT	GTA	528
Glu	Gly	Glu	Val	Phe	Asp	Ser	Val	Lys	Pro	Gly	Leu	Ser	Ala	Phe	Val	80
																85
GAT	CAA	CCT	AAG	CAG	GGT	GCT	GAG	ACC	GTT	CAA	GGG	CTC	TTA	GAG	GTG	576
Asp	Gln	Pro	Lys	Gln	Gly	Ala	Glu	Thr	Vall	Gln	Gly	Leu	Leu	Glu	Val	95
																100
GCC	AAA	GAC	TCA	ATC	CCC	CGA	AGT	CAC	TGG	AAA	AAG	ACC	CCA	GTG	GTC	624
Ala	Lys	Asp	Ser	Ile	Pro	Arg	Ser	His	Trp	Lys	Lys	Thr	Pro	Val	Val	115
																120
CTA	AAG	GCA	ACA	GCA	GGA	CTA	CGC	TTA	CTG	CCA	GAA	CAC	AAA	GCC	AAG	672
Leu	Lys	Ala	Thr	Ala	Gly	Leu	Arg	Leu	Leu	Pro	Glu	His	Lys	Ala	Lys	130
																135
GCT	CTG	CTC	TTT	GAG	GTA	AAG	GAG	ATC	TTC	AGG	AAG	TCA	CCT	TTC	CTG	720
Ala	Leu	Leu	Phe	Glu	Val	Lys	Glu	Ile	Phe	Arg	Lys	Ser	Pro	Phe	Leu	145
																150
																155

FIG. 7B



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
34/46

GTA	CCA	AAG	GGC	AGT	GTT	AGC	ATC	ATG	GAT	GGA	TCC	GAC	GAA	GGC	ATA	768
Val	Pro	Lys	Gly	Ser	Val	Ser	Ile	Met	Asp	Gly	Ser	Asp	Glu	Gly	Ile	
160																165
TTA	GCT	TGG	GTT	ACT	GTG	AAT	TTT	CTG	ACA	GGT	CAG	CTG	CAT	GGC	CAC	816
Leu	Ala	Trp	Val	Thr	Val	Asn	Phe	Leu	Thr	Gly	Gln	Leu	His	Gly	His	
175																180
AGA	CAG	GAG	ACT	GTG	GGG	ACC	TTG	GAC	CTA	GGG	GGA	GCC	TCC	ACC	CAA	864
Arg	Gln	Glu	Thr	Val	Gly	Thr	Leu	Asp	Leu	Gly	Gly	Ala	Ser	Thr	Gln	
																195
ATC	ACG	TTC	CTG	CCC	CAG	TTT	GAG	AAA	ACT	CTG	GAA	CAA	ACT	CCT	AGG	912
Ile	Thr	Phe	Leu	Pro	Gln	Phe	Glu	Lys	Thr	Leu	Glu	Gln	Thr	Pro	Arg	
																210
GGC	TAC	CTC	ACT	TCC	TTT	GAG	ATG	TTT	AAC	AGC	ACT	TAT	AAG	CTC	TAT	960
Gly	Tyr	Leu	Thr	Ser	Phe	Glu	Met	Phe	Asn	Ser	Thr	Tyr	Lys	Leu	Tyr	
																225
ACA	CAT	AGT	TAC	TTG	GGA	TTT	GGA	TTG	AAA	GCT	GCA	AGA	CTA	GCA	ACC	1008
Thr	His	Ser	Tyr	Leu	Gly	Phe	Gly	Leu	Lys	Ala	Ala	Arg	Leu	Ala	Thr	
																240
																250

FIG. 7C



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
35/46

CTG	GGA	GCC	CTG	GAG	ACA	GAA	GGG	ACT	GAT	GGG	CAC	ACT	TTC	CGG	AGT	1056
Leu	Gly	Ala	Leu	Glu	Thr	Glu	Gly	Thr	Asp	Gly	His	Thr	Phe	Arg	Ser	255
																260
																265
																270
																275
																280
																285
																290
																295
																300
																305
																310
																315
																320
																325
																330
																335
																340
																345
																350
																355

FIG. 7D

O I P E
MAR 22 2004
PATENT & TRADEMARK OFFICE
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
36/46

AAA	GTT	GAA	GAT	TTT	GAA	AGA	AAA	GCC	AGG	GAA	GTG	TGT	GAT	AAC	TTG	1344
Lys	Vall	Glu	Asp	Phe	Glu	Arg	Lys	Ala	Arg	Glu	Val	Cys	Asp	Asn	Leu	365
																365
GAA	AAC	TTC	ACC	TCA	GGC	AGT	CCT	TTC	CTG	TGC	ATG	GAT	CTC	AGC	TAC	1392
Glu	Asn	Phe	Thr	Ser	Gly	Ser	Pro	Phe	Leu	Cys	Met	Asp	Leu	Ser	Tyr	380
																380
ATC	ACA	GCC	CTG	TTA	AAG	GAT	GGC	TTT	GGA	GAC	AGC	ACA	GTC			1440
Ile	Thr	Ala	Leu	Leu	Lys	Asp	Gly	Phe	Gly	Phe	Ala	Asp	Ser	Thr	Val	395
																395
TTA	CAG	CTC	ACA	AAG	AAA	GTG	AAC	AAC	ATA	GAG	ACG	GGC	TGG	GCC	TTG	1488
Leu	Gln	Leu	Thr	Lys	Lys	Val	Asn	Asn	Ile	Glu	Thr	Gly	Trp	Ala	Leu	400
																400
GGG	GCC	ACC	TTT	CAC	CTG	TTG	CAG	TCT	CTG	GGC	ATC	TCC	CAT			1530
Gly	Ala	Thr	Phe	His	Leu	Leu	Gln	Ser	Leu	Gly	Ile	Ser	His			415
																420
																425
TGAGGCCACG TACTTCCTTG GAGACCTGCA TTTGCCAACA CCTTTTAAG GGGAGGAGAG 1590																

FIG. 7E



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
37/46

AGCACTTAGT TTCTGAACTA GTCTGGACA TCCTGGACTT GAGCCTAGAG ATTAGGTT 1650
AATTAATT ACACATCTAA TGTGAAC TGCGCTAACCA CTCAAAGAGTA CACAGCTGGC 1710
ACCAGAGCAT CACAGAGGC CCTGTGAGCC AAAAAGTATA GTTTGGAAC TTAACCTTGG 1770
AGTGAGAGCC CAGGGACAGG TCCCTGGAAA CCAAAGAAAA ATCGCATTT AACCCTTTGA 1830
GTGCCCTCATT CCACCTGAATA TTTAAATT CCTCTTAAT GGTAAACTGA CTTATTGCAA 1890
TCCCAAGACC CATCAAATAC AGTATTTT TCCTCCCTAT ACAGTGCCTT GCCCACCCCTT 1950
ATCTGCACCC ACCTCCCCCTG AAAAGAGAG AAAAAGAAA AAAAAGAAA 1998

FIG. 7F

Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
38/46



CD39L2	1	M K K G I R Y E T S R K T S Y I F Q Q P Q H G P W Q T R M R K I S N H G S L R V A K V A Y P L G L C V G V F I Y V A Y I	- - - - - M A T S W G
CD39L4	1	- - - - -	- - - - -
CD39L1	1	- - - - -	- - - - -
CD39L3	1	- - - - - M F T V L T R Q P C E Q A G L	- - - - - M E D T K E
CD39	1	- - - - -	- - - - -
CD39L2	61	K W H R A T A T Q A F F S I T R A A P G A R W G Q Q A H - S P L G T A A D G H E V F Y G I M F D A G S T G T R V H V F Q	ACR I
CD39L4	7	T V F F M L V V S C V C S A V S H R N Q Q T W F E G I F L S S M C P I N V S A S T L Y G I M F D A G S T G T R I H V Y T	
CD39L1	1	- - - M A G K V R S L L P P L L A A A G L A G L L L C V P T R D V R E P ? A L K Y G I V L D A G S S H T S M F I Y K	
CD39L3	16	K A L Y R T P T I I A L V V L L V S I V V L V S I T V I Q I H K Q E V L - P P G L K Y G I V L D A G S S R T T V Y V Y Q	
CD39	7	S N V K T F C S K N I L A I L G F S S I I A V I A L L A V G L T O N K A L P E N V K Y G I V L D A G S S H T S L Y I Y K	
CD39L2	120	F T - R P P R E T P T L T H E T F K A V K - P G L S A Y A D D V E K S A Q G I R E L L D V A K Q D I P P D F W K A T P L	ACR II
CD39L4	67	F V Q K M P G Q L P I L E G E V F D S V K - P G L S A F V D Q P K Q G A E T V Q G L L E V A K D S I P R S H W K K T P V	
CD39L1	58	W P A D K E N D T G I V G Q H S S C D V P G G G I S S Y A D N P S G A S Q S L V G C L E Q A L Q D V P K E R H A G T P L	
CD39L3	75	W P A E K E N N T G V V S Q T F K C S V K G S G I S S Y G N N P Q D V P R A F E E C M Q K V K G Q V P S H L H G S T P I	
CD39	67	W P A E K E N D T G V V H Q V E E C / R V K G P G I S K F V Q K V N E I G I Y L T D C M E R A R E V I P R S Q H Q E T P V	

FIG. 8A

Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES

AND NUCLEIC ACIDS

Applicants: Chadwick et al.

Docket No. 28110/36120C

39/46

MAR 22 2004

PATENT & TRADEMARK OFFICE
U.S.



		ACR III
CD39L2	178.	VLKATAGLRL - - - PGEKAQKLLQKVKEVFKASSPFLVGGDDCVS 
CD39L4	126	VLKATAGLRL - - - PEHKAKALLFEVKEIFRKSPFLVPKGSV 
CD39L1	118	YLGATAGMRLNLNTNPEASTSVLMAVTHLTQYPF - - DFRGARILSGQEEGVFGWVTANY
CD39L3	135	HLGATAGMRLRLQNETAANEVLESIQSSYFKSQPF - - DFRGAQIISGQEEGVYGWITANY
CD39	127	YLGATAGMRLRMESSEELADRVLDDVERSLSNYPF - - DFOGARILITGQEEGAYGWITINY
		ACR IV
CD39L2	235	L TGSL - - - - - KTPGGSSVGMLDLGGGSTQIAFLPRVEGTLQASPPPGYLTALRM
CD39L4	183	L TGQL - - - - - HGHROETVGTLDLGGA STQITFLPQFEKTLEQTTPRGYLTSSFEM
CD39L1	176	LL ENFIKYGWVGWF - - RPR - KGT LGAMDLGGASTQITFETTSPAE DRASE - - V - QLHL
CD39L3	193	LMGNFLEKNLWHMWV - - HP HG VETTGALDLGGASTQISFVAGEKMDLNTSD - - IMQVSL
CD39	185	LL GKFPSQKTRWF SI VPYETNNQETT F GALDLGGASTQITFVTPQNTIESPDN - - ALQF RL
		ACR II
CD39L2	283	FNR TYKLYSYYLGLGMSARLA ILGGVEGQPAKD GKELVSPCLSPSFKG EW EHAEV T YR
CD39L4	231	FN STYKLYTHSYLGFGLKAARLATLGALETE - GTDGHTFRSACLPRWLEAEWIFGGV KYQ
CD39L1	229	YGQHYR VYTHSFLCYGRDQVLQRLL - ASALQ - - - THGFHPCWP RGFS T QVILLGDVYQS
CD39L3	248	YGYVYTYLHSFQCYGRNEAEKKFL - AMLLQNSPTKHNHLTNPCYPRDY SISFTM GHV FDS
CD39	242	YGKDYNVYTHSFLCYGKDKQALWQKL - AKDIOQVASSNEI - LRDPCFPHPGYKKVVNV S DLYK T

FIG. 8B



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
40/46

CD39L2	343	V S G Q K A A S L H E L C A A R V S E V L Q N R V H R T E E V K H V D F Y A F S Y Y Y D L A A G V G L I D A E K G G S
CD39L4	290	Y G G N Q E G E V G G F E P C Y A E V L R V V R G K L H Q P E E V Q R G S F Y A F S Y Y Y D R A V D T D M I D Y E K G G I
CD39L1	283	P C T M A Q R P Q N F N S S A R V S L S G S S D P H L C R D L V S G L F S F S S C - P F S R C S F N G V F Q P P V A G N
CD39L3	307	L C T V D Q R P E S Y N P N D V I T F E G T G D P S L C K E K V A S I F D F K A C H D Q E T C S F D G V Y Q P K I K G P
CD39	300	P C T - - K R F E M T L P F Q Q F E I L Q G I G N Y Q Q C H Q S I L E L F N T S Y C - P Y S Q C A F N G I F L P P L Q G D
CD39L2	403	L V V G D F E I A A K Y V C R T L E T Q P O S S S P F S C M D L T Y V S L L Q E - F G F P R S K V L K L T R K I D N V E
CD39L4	350	L K V E D F E R K A R E V C D N L E N F T S G S P F L C M D L S Y I T A L L K D G F G F A D S T V L Q L T K V N N I E
CD39L1	342	F V - - - - A F S A F F Y T V D F L R T S M G L P V A T L Q Q L E A A V N V C N Q T W A Q - - - - -
CD39L3	367	F V - - - - A F A G F Y Y T A S A L N L S G S F - - - S L D T F N S S T W N F C S Q N W S Q L P L L L P K F D E V Y
CD39	357	F G - - - - A F S A F Y F V M K F L N L T S - - E K V S Q E K V T E M M K K F C A Q P W E E I K T S Y A G V K E K Y
CD39L2	462	T S W A L G A I F H Y I D S L N R Q K S P A S *
CD39L4	410	T G W A L G A T F H L L Q S L G I S H
CD39L1	384	- - - - - Q L L S R G Y G F D E R A F G G V I F Q K K A A D T A V G W A L G Y M L N L T N L I P A D P P G
CD39L3	418	A R S Y C F S A N Y I Y H L F V N G Y K F T E E T W P Q I H F E K E V G N S S I A W S L G Y M L S L T N Q I P A E S P L
CD39	409	L S E Y C F S G T Y I L S L L Q G S D A G W T L G Y M L N L T N M I P A E Q P -

FIG. 8C



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
41/46

CD39L2	485	
CD39L4	429	
CD39L1	432	<u>L R K G T D F S S W V</u> <u>L L L F A S</u> <u>S A L V L L R Q V</u> <u>H S A K L P S T I *</u>
CD39L3	478	<u>I R L P I E P P V F V G T L A F F T V A A</u> <u>L C S A T R R K R H S E H A F D H A V D S D *</u>
CD39	468	<u>L S T P L S H S T Y V F L M V L F S L V L F T V A I I G L L I F H K P S Y F W K D M V *</u>

FIG. 8D



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES

AND NUCLEIC ACIDS

Applicants: Chadwick et al.

Docket No. 28110/36120C

42/46

PeaGDP	1	- - - - -	- - - - -	- - - - -	<u>M</u>
Potapyrase	1	- - - - -	- - - - -	- - - - -	<u>MLNQN</u>
CD39L2	1	<u>MKKGIRYETSRKTSYIFQQPQHGPWQTRMRKISNHGSILRVAKVAYPLGLCVGVFIYVAYI</u>	- - - - -	- - - - -	
CD39L4	1	- - - - -	- - - - -	- - - - -	<u>MATSWG</u>
dNTPase	1	- - - - -	- - - - -	- - - - -	<u>MKEYEKLLATDEKPPRKRSSGSPNASSGGNRGPGSGL</u>
yGDPase	1	- - - - -	- - - - -	- - - - -	<u>KTPE</u>
ACRI					
peaGDP	2	<u>EELLKLITFLFSMPAITSSQYLGNNL-LTSRKIPLKQEEISSYYAVVFDAGGSTGSRVHVF</u>	<u>DAGGSTGSRVHVF</u>	<u>DAGGSTGSRVHVF</u>	
potapyrase	6	<u>SHEFIFLILAIFLVLPLSLLPSLISKNVNNAQI-PLRRHLLSHES-E-HYAVIFDAGGSTGSRVHVF</u>	<u>HYAVIFDAGGSTGSRVHVF</u>	<u>HYAVIFDAGGSTGSRVHVF</u>	
CD39L2	61	<u>KWHRATATQAFPSITRAAPGARWGQQA-H-SPLGTAADGHEVFGIMFYGIMFDAGGSTGTRVHVF</u>	<u>FIMFYGIMFDAGGSTGTRVHVF</u>	<u>FIMFYGIMFDAGGSTGTRVHVF</u>	
CD39L4	7	<u>TYFFMLVVSCVCSSAVSHRNQQTWPEGI-FLSSSMCPINVSASTLYGIMFDAGGSTGTRVHVF</u>	<u>TYFFMLVVSCVCSSAVSHRNQQTWPEGI-FLSSSMCPINVSASTLYGIMFDAGGSTGTRVHVF</u>	<u>TYFFMLVVSCVCSSAVSHRNQQTWPEGI-FLSSSMCPINVSASTLYGIMFDAGGSTGTRVHVF</u>	
dNTPase	37	<u>KISFLCLIIISVILLFLVFVSENASA-P-YLARLASKFGYSKVQYAAIIDAGGSTGSRVLAY</u>	<u>YLARLASKFGYSKVQYAAIIDAGGSTGSRVLAY</u>	<u>YLARLASKFGYSKVQYAAIIDAGGSTGSRVLAY</u>	
yGDPase	5	<u>DISILPVNDEPGYLQDSKTEQNYPELADAVKSQTSQTCSEEHKYVIMIDAGGSTGSRVHIV</u>	<u>DISILPVNDEPGYLQDSKTEQNYPELADAVKSQTSQTCSEEHKYVIMIDAGGSTGSRVHIV</u>	<u>DISILPVNDEPGYLQDSKTEQNYPELADAVKSQTSQTCSEEHKYVIMIDAGGSTGSRVHIV</u>	

FIG. 9A



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS

Applicants: Chadwick et al.
Docket No. 28110/36120C

43/46

peaGDP	61	H F N Q N L D L L H I G K G V E Y Y N K I T P G L S S Y A N N P E Q A A K S L I P P L E Q A E D V V P D D L Q P K T P V	ACR II
potapyrase	63	R E D E K L G L L P I G N N I E Y F M A T E P G L S S Y A E D P K A A A N S L E P L L D G A E G V V P O E L Q S E T P L	
CD39L2	119	Q F T - R P P R E T P T L T H E T F K A V K P G L S A Y A D D V E K S A Q G I R E L L D V A K Q D I P F D F W K A T P L	
CD39L4	66	T F V Q K M P G Q L P I L E V F D S V K P G L S A F V D Q P K Q G A E T V Q G L L E V A K D S I P R S H W K K T P V	
dNTPase	96	K F N R S F I D N K L V Y E E L E K E R K P G L S S F A D N P A E G A H S I K L L D E A R A F I P K E H W S S T P L	
yGDPase	65	K F D - - V C T S S P P T L L D E K F D M L E P G L S S F D T D S V G A A N S L D P U L K V A M N Y V P I K A R S C T P V	
		↓	ACR II
peaGDP	121	R L G A T A G L R L L N G D A S E K I L Q S V R D M L S N R S T F - N V Q P D A V S I I D G T Q E G S Y L W V T V N Y A	ACR II
potapyrase	123	E L G A T A G L R M L K G D A A E K I L Q A V R N L V K N Q S T F - H S K D Q W V T I L D G T Q E G S Y M W A A I N Y L	
CD39L2	178	V L K A T A G L R L L P G E K A Q K L L Q K V K E V F K - A S P F - L V G D D C V S I M N G T D E G V S A W I T I N F L	
CD39L4	126	V L K A T A G L R L L P E H K A K A L L F E V K E I F R - K S P F - L V P K G S V S I M D G S D E G I L A W V T V N F L	
dNTPase	156	V L K A T A G L R L L P A S K A E N I L N A V R D L F A - K S E F - S V D M D A V E I M D G T D E G I F S W F T V N F L	
yGDPase	123	A V K A T A G L R L L G D A K S S K I L S A V R D H L E K D Y P F P V V E G D G V S I M G G D E E G V F A W I T T N Y L	
		↓	ACR II

FIG. 9B



**Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS**

Applicants: Chadwick et al
Docket No. 28110/36120C

44/46

ACR IV

peaGDP	180	<u>L G N L G K K Y T K - - T V G V I D L G G G S V Q M A Y A V S K K T A K N A P K V A D G D D P Y I K K V V L K G I P Y D</u>
Potapyrase	182	<u>L G N L G K D Y K S - - T T A T I D L G G G S V Q M A Y A I S N E Q F A K A P Q N E D G - E P Y V Q Q K H L M S K D Y N</u>
CD39L2	236	<u>T G S L K T P G G S - - S V G M L D L G G G S T Q I A F L P R V E G - - - - T L Q A S P P G Y L T A L R M F N R T Y K</u>
CD39L4	184	<u>T G Q L H G H R Q E - - T V G T L D L G G A S T Q I T F L P Q F E K - - - - T L E Q T P R G Y L T S F E M F N S T Y K</u>
dNTPase	214	<u>L G R L S K T N Q A - - A A - - L D L G G G S T Q V T F S P T D P D - - - - Q V P V Y D K - Y M H E V V T S S K K I N</u>
yGDPase	183	<u>L G N I G A N G P K L P T A A V F D L G G G S T Q I V F E P T F P I N E K M V - - - - D G E H K F D L K F G D E N Y T</u>

peaGDP	238	<u>L Y V H S Y L H F G R E A S R A E I L K L T P R S P</u>	- - - - -	<u>N P C L L A G F N G</u>	- - - - -	<u>I Y</u>
potapyrase	239	<u>L Y V H S Y L N Y G Q L A G R A E I F K A S R N E S</u>	- - - - -	<u>N P C A L E G C D G</u>	- - - - -	<u>Y Y</u>
CD39L2	289	<u>L Y S Y S Y L G L G L M S A R L A I L G G V E G Q P A K D G K E L V</u>	- - - - -	<u>S P C L S P S P F K G</u>	- - - - -	<u>E - W</u>
CD39L4	237	<u>L Y T H S Y L G F G L K A A R L A T L G A L E T E - G T D G H T F R</u>	- - - - -	<u>S A C L P R W L E A</u>	- - - - -	<u>E - W</u>
dNTPase	264	<u>V F T H S Y L G L G L M A A R H A V F - - T H G Y K K E D T V L E</u>	- - - - -	<u>S V C V N P I I A N</u>	- - - - -	<u>R T W</u>
YGDPase	238	<u>L Y Q F S H L G Y G L K E G R N K V N S V L V E N A L K D G K I L K G D N T K T H Q L S S P C L P P K V N A T N E K V T</u>	- - - - -			

FIG. 9C



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
45/46

peaGDP	276	<u>TYSGE</u> <u>EFKATA</u> <u>YTS</u> <u>G</u> - <u>ANF</u> <u>NKCK</u> <u>KNT</u> <u>IRK</u> <u>ALKLN</u> <u>YPCPYQ</u> <u>NC</u> <u>TFGGI</u> <u>WNGG</u> - - <u>GGNGQ</u> <u>KN</u>
potapyrase	277	<u>SYGGV</u> <u>DYKVKA</u> <u>PKK</u> <u>G</u> - <u>SSWKRCRRLTRH</u> <u>ALKINAKCNIE</u> <u>ECTFNGVWNGG</u> - - <u>GGDGQ</u> <u>KN</u>
CD39L2	335	<u>EHAEV</u> <u>TYRVSGQ</u> <u>KAASLHE</u> <u>LCAAR</u> - - <u>VSEV</u> - - - <u>LQNRV</u> - - - <u>HRT</u> - - <u>EEVKHV</u> <u>D</u>
CD39L4	282	<u>IFGGVK</u> <u>QYQGGNQE</u> <u>EGEVGF</u> <u>PCYAE</u> - - <u>VLRV</u> - - - <u>VRGKL</u> - - - <u>HQP</u> - - <u>EEVQRGS</u>
dNTPase	308	<u>TYGNVQYKVSGKENGKSSAEQPIVDFDACLEL</u> - - - <u>VKS</u> <u>SKVMP</u> <u>VLVKPKP</u> - - <u>FTLKQH</u> <u>A</u>
yGDPase	298	<u>LESKETTYTIDFIGPDEPSGAQCRFLTD</u> <u>EILNKDAQCCQSPPCSFNGVHQPSLVRTPKESND</u>
peaGDP	332	<u>LPASSSFFYLPEDTGMVDA</u> <u>STPNF</u> <u>FILRPVDIE</u> <u>TAKAKEACALNFEDAKS</u> <u>TYPF</u> <u>FLDKKK</u> <u>NVAS</u>
potapyrase	333	<u>IHASFFFFYDIGAQVGIVDTKFP</u> <u>SALAKP</u> <u>IQYLNAAKVACQ</u> <u>QTNVADIKSIEPKTS</u> <u>QDRNI</u> - <u>P</u>
CD39L2	379	<u>FYAFSYYD</u> <u>DLAAGVGLIDAE</u> - <u>KGGSLVVGD</u> <u>DFEIAAKYVCRT</u> - - - - - <u>LETQPKQSSP</u>
CD39L4	326	<u>FYAFSYYDRAVDTMIDYE</u> - <u>KGGGILKVEDFERKAREV</u> <u>CDN</u> - - - - - <u>LENFTSGSP</u>
dNTPase	360	<u>VAAFSSYYFERAIESGLVDPL</u> - <u>AGGETTVEAYRKKAQEICAI</u> - - - - - <u>PNDE</u> - - <u>Q</u> <u>P</u>
yGDPase	358	<u>IYIFSYFYDRT</u> <u>RPLGMPLSFTLNE</u> <u>LNDLARI</u> <u>VCKGEETWNNSVFSGIAGS</u> <u>SL</u> - - <u>DELESDS</u>

FIG. 9



Title: METHODS AND COMPOSITIONS
RELATING TO CD-39-LIKE POLYPEPTIDES
AND NUCLEIC ACIDS
Applicants: Chadwick et al.
Docket No. 28110/36120C
46/46

peaGDP	392	<u>Y V C M D L I Y Q Y V L L V D G F G L D P L Q K I T S G K E I E Y Q D A I V E A A W P L G N A V E A I S A L P K F E R L</u>
Potapyrase	392	<u>Y L C M D L I Y E Y T L L V D G F G L N P H K E I T V I H D V Q Y K N Y L V G A A W P L G C A I D L V S S T T N K I R V</u>
CD39L2	428	<u>F S C M D L T Y V S L L Q E - F G F P R S K V L K L T R K I D N - - - V E T S W A L G A I F H Y I D S L N R Q K S P</u>
CD39L4	375	<u>F L C M D L S Y I T A L L K D G F G F A D S T V L Q L T K K V N N - - - I E T G W A L G A T F H L L Q S L G I S H</u>
dNTPase	406	<u>F M C F D L T F I S T L L R E G F G L N D G K K I K L Y K K I D G - - - H E I S W A L G C A Y N V L T S D E K F S N S</u>
yGDPase	415	<u>H F C L D L S F Q V S L L H T G Y D I P L Q R E L R T G K K I A N K - - - E I G W C L G A S L P L L K A D N W K C K I</u>

peaGDP	452	M Y F V
potapyrase	452	<u>A S S *</u>
CD39L2	483	<u>A S *</u>
CD39L4	429	
dNTPase	462	
yGDPase	471	<u>Q S A</u>

FIG. 9E